Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase.
暂无分享,去创建一个
H. Deeg | U. Popat | J. Capo-Chichi | A. Gerds | R. Sobecks | Vikas Gupta | J. Kennedy | W. Saber | R. Salit | B. Scott | E. Alyea | Zhen-Huan Hu | Soyoung Kim | R. Nakamura | Zhen-Huan Hu
[1] Jiqiang Yao,et al. Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) , 2019, Blood.
[2] P. Vyas,et al. The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results , 2019, Blood.
[3] E. Papaemmanuil,et al. Landscape of TP53 Mutations in MPN , 2019, Blood.
[4] M. Minden,et al. Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. , 2019, Blood advances.
[5] V. Najfeld,et al. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] M. Heuser,et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. , 2019, Blood.
[7] Lixin Yang,et al. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. , 2019, Blood advances.
[8] O. Odenike. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. , 2018, Blood.
[9] M. Minden,et al. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. , 2018, Blood advances.
[10] R. Hoffman,et al. Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. , 2018, Leukemia research.
[11] P. A. Futreal,et al. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Markus G. Manz,et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.
[13] D. Birnbaum,et al. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms , 2018, American journal of hematology.
[14] A. Tefferi,et al. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. , 2018, Blood advances.
[15] P. Guglielmelli,et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts , 2018, Leukemia.
[16] W. Hiddemann,et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia , 2017, Leukemia.
[17] L. Miguet,et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. , 2018, The New England journal of medicine.
[18] M. Minden,et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. , 2017, Blood advances.
[19] D. Neuberg,et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.
[20] D. Birnbaum,et al. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases , 2017, Haematologica.
[21] M. Kurokawa,et al. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] Obi L. Griffith,et al. GenVisR: Genomic Visualizations in R , 2016, bioRxiv.
[23] S. Armstrong,et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms , 2014, Proceedings of the National Academy of Sciences.
[24] M. Robin,et al. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) , 2014, Bone Marrow Transplantation.
[25] N. Kröger,et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] M. Minden,et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. , 2013, Blood.
[27] M. Konopleva,et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[28] R. Mesa,et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. , 2012, Leukemia research.
[29] M. Cazzola,et al. p53 lesions in leukemic transformation. , 2011, The New England journal of medicine.
[30] V. Najfeld,et al. Therapeutic options for patients with myelofibrosis in blast phase. , 2010, Leukemia research.
[31] A. Green,et al. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. , 2010, The New England journal of medicine.
[32] O. Abdel-Wahab,et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.
[33] B. Sandmaier,et al. Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[34] H. Kantarjian,et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. , 2008, Blood.
[35] J. Klein,et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[36] Francisco Cervantes,et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). , 2007, Leukemia research.
[37] R. Mesa,et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. , 2005, Blood.
[38] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[39] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .